Immunology Biosimilars Market

Adalimumab leads the immunology biosimilars market with a 30.3% share in 2026, followed by rheumatoid arthritis at 31.3%. Market demand depends on established switching pathways, long-term treatment continuity, and payer reimbursement policies, while dependable supply and formulary implementation remain essential for sustained adoption.